UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

The New England journal of medicine, 2010-09, Vol.363 (12), p.1117-1127

2010

Volltextzugriff (PDF)

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.799-807

2012

Volltextzugriff (PDF)

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

Journal of clinical oncology, 2013-04, Vol.31 (10), p.1285-1292

2013

Volltextzugriff (PDF)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Journal of hematology and oncology, 2018-08, Vol.11 (1), p.101-101, Article 101

2018

Volltextzugriff (PDF)

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Haematologica (Roma), 2013-12, Vol.98 (12), p.1865-1871

2013

Volltextzugriff (PDF)

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis

British journal of haematology, 2013-05, Vol.161 (4), p.508-516

2013

Volltextzugriff (PDF)

Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement

Cancer, 2011-04, Vol.117 (21), p.4869-4877

2011

Volltextzugriff (PDF)

Evaluating the Serial Use of the Myelofibrosis Symptom Assessment Form for Measuring Symptomatic Improvement: Performance in 87 Myelofibrosis Patients on a JAK1 and JAK2 Inhibitor (INCB018424) Clinical Trial

Cancer, 2011-11, Vol.117 (21), p.4869-4877

2011

Volltextzugriff (PDF)

Potency of Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) Used in Combination with Other Human Immunodeficiency Virus NNRTIs, NRTIs, or Protease Inhibitors

Antimicrobial Agents and Chemotherapy, 2002-06, Vol.46 (6), p.1640-1646

2002

Volltextzugriff (PDF)

Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors

Journal of medicinal chemistry, 2000-05, Vol.43 (10), p.2019-2030

2000

Volltextzugriff (PDF)

Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors

Science (American Association for the Advancement of Science), 1994-01, Vol.263 (5145), p.380-384

1994

Volltextzugriff (PDF)

Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors

Bioorganic & medicinal chemistry letters, 2000-08, Vol.10 (15), p.1729-1731

2000

Volltextzugriff (PDF)

A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS7058-TPS7058

2021

Volltextzugriff (PDF)

DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants

Antimicrobial Agents and Chemotherapy, 2002-05, Vol.46 (5), p.1394-1401

2002

Volltextzugriff (PDF)

Synthesis and evaluation of analogs of Efavirenz (SUSTIVA TM) as HIV-1 reverse transcriptase inhibitors

Bioorganic & medicinal chemistry letters, 1999-10, Vol.9 (19), p.2805-2810

1999

Volltextzugriff (PDF)

The regulation of sequential processing of HIV-1 Gag by the viral protease

Advances in experimental medicine and biology, 1998, Vol.436, p.15

1998

Volltextzugriff (PDF)

Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule

Drug discovery today, 1997, Vol.2 (1), p.6-18

1997

Volltextzugriff (PDF)

4,1-Benzoxazepinone analogues of efavirenz (Sustiva™) as HIV-1 reverse transcriptase inhibitors

Bioorganic & medicinal chemistry letters, 2001-06, Vol.11 (11), p.1389-1392

2001

Volltextzugriff (PDF)

Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors

Bioorganic & medicinal chemistry letters, 2000-01, Vol.10 (2), p.193-195

2000

Volltextzugriff (PDF)

DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants

Antimicrobial Agents and Chemotherapy, 2001-11, Vol.45 (11), p.3021-3028

2001

Volltextzugriff (PDF)

Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase

Bioorganic & medicinal chemistry letters, 2001-02, Vol.11 (3), p.309-312

2001

Volltextzugriff (PDF)

3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors

Bioorganic & medicinal chemistry letters, 2001-01, Vol.11 (2), p.211-214

2001

Volltextzugriff (PDF)

Expanded-Spectrum Nonnucleoside Reverse Transcriptase Inhibitors Inhibit Clinically Relevant Mutant Variants of Human Immunodeficiency Virus Type 1

Antimicrobial Agents and Chemotherapy, 1999-12, Vol.43 (12), p.2893-2897

1999

Volltextzugriff (PDF)

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer and Systemic Inflammation

Clinical lung cancer, 2018-09, Vol.19 (5), p.e567-e574

2018

Volltextzugriff (PDF)

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

Journal of hematology and oncology, 2013-10, Vol.6 (1), p.81-81, Article 81

2013

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(86)

Publikationsform

Sprache

Englisch
(93)
Japanisch
(17)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis

Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement

Evaluating the Serial Use of the Myelofibrosis Symptom Assessment Form for Measuring Symptomatic Improvement: Performance in 87 Myelofibrosis Patients on a JAK1 and JAK2 Inhibitor (INCB018424) Clinical Trial

Potency of Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) Used in Combination with Other Human Immunodeficiency Virus NNRTIs, NRTIs, or Protease Inhibitors

Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors

Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors

Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors

A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis

DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants

Synthesis and evaluation of analogs of Efavirenz (SUSTIVA TM) as HIV-1 reverse transcriptase inhibitors

The regulation of sequential processing of HIV-1 Gag by the viral protease

Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule

4,1-Benzoxazepinone analogues of efavirenz (Sustiva™) as HIV-1 reverse transcriptase inhibitors

Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors

DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants

Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase

3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors

Expanded-Spectrum Nonnucleoside Reverse Transcriptase Inhibitors Inhibit Clinically Relevant Mutant Variants of Human Immunodeficiency Virus Type 1

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer and Systemic Inflammation

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

Suchergebnisse filtern